16 completed, 7 active not recruiting, 5 terminated, 5 unknown. 12 Phase 2, 8 Not applicable, 7 Phase 3, 3 Phase 1, 1 Early Phase 1.
Follow Antibody-mediated Rejection: new trials by email Literature Review of Antibody-mediated Rejection trials Research Report on Antibody-mediated Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD38 mAb Induction + Azathioprine Maintenance for Chronic Active AMR in Kidney Transplant Recipients CD38, Azathioprine (AZA), Standard Triple Immunosuppression Maintenance - Kidney Transplantation, Antibody-mediated Rejection | Not applicable | Not yet recruiting | wujianyong | 20 | 2026-07-15 | 2026-07-21 |
| Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial Methylprednisolone (MP), Daratumumab, Telitacicept - Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR) | Phase 2 | Active not recruiting | First Affiliated Hospital, Sun Yat-Sen University | 20 | 2026-06-20 | 2026-10-29 |
| A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) Felzartamab - Antibody-mediated Rejection, Microvascular Inflammation | Phase 3 | Enrolling by invitation | Biogen | 201 | 2026-04-16 | 2026-11-02 |
| TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS Graft Rejection, Kidney Transplantation | Active not recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 30 | 2025-04-10 | 2026-01-05 | |
| Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation ALXN2030, Placebo - Antibody-Mediated Rejection, Kidney Transplantation | Phase 2 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 47 | 2025-03-07 | 2026-08-11 |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) Felzartamab, Placebo - Antibody-mediated Rejection | Phase 3 | Active not recruiting | Biogen | 132 | 2024-12-03 | 2026-06-05 |
| Isatuximab in Lung Transplant Recipients Isatuximab, bone marrow biopsy - Antibody-mediated Rejection, Allosensitization | Early Phase 1 | Withdrawn | NYU Langone Health | 2024-12-01 | 2025-04-11 | |
| A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe - Antibody-mediated Rejection | Phase 2 | Active not recruiting | argenx | 33 | 2024-08-30 | 2026-07-02 |
| A Prospective Randomized Trial of ECP in Subclinical AMR Extracorporeal Photopheresis - Antibody-mediated Rejection, Lung Transplant Rejection | Not applicable | Recruiting | Medical University of Vienna | 80 | 2024-03-01 | 2024-07-09 |
| The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation Daratumumab - Antibody-mediated Rejection, Kidney Tranplant | Not applicable | Unknown | First Affiliated Hospital of Zhejiang University | 15 | 2023-05-23 | 2023-09-14 |
| TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients Tocilizumab - Antibody-mediated Rejection | Phase 3 | Active not recruiting | Vastra Gotaland Region | 50 | 2022-02-01 | 2026-08-10 |
| Incidence, Course and Outcome of ABMR in Kidney Transplantation Kidney Transplantation, Immunosuppression, Nephrectomy (kidney donation) - Antibody-mediated Rejection, Kidney Transplantation | Unknown | University Medical Center Groningen | 225 | 2022-01-01 | 2023-05-11 | |
| Felzartamab in Late Antibody-Mediated Rejection Felzartamab, Placebo - Antibody-mediated Rejection | Phase 2 | Completed | Farsad Eskandary | 22 | 2021-10-06 | 2024-04-18 |
| Biorepository and Registry for Plasma Exchange Patients Antibody-mediated Rejection, NMO Spectrum Disorder | Recruiting | Charles M Knudson | 200 | 2021-07-28 | 2025-05-20 | |
| Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection Kidney allograft biopsy depending on donor-derived cell-free DNA levels - Kidney Transplant Rejection, Antibody-mediated Rejection | Not applicable | Completed | Charite University, Berlin, Germany | 40 | 2021-06-01 | 2025-01-22 |
| MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT) Echocardiogram, Cardiac magnetic resonance, Coronary angiography - Transplant Failure, Heart Transplant Rejection | Active not recruiting | Juan Francisco Delgado Jimenez | 90 | 2021-04-01 | 2022-06-21 | |
| DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients Antibody-mediated Rejection | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 300 | 2021-01-22 | 2022-05-27 | |
| Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT 5-gene classification model - ABO Blood Type Incompatible Kidney Transplantation, Antibody-mediated Rejection | Not applicable | Completed | Seoul National University Hospital | 30 | 2020-05-19 | 2025-05-15 |
| Desensitization in Kidney Allograft Using Daratumumab Daratumumab dose escalation, Daratumumab full dose - Allosensitization, Kidney Transplant Rejection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 21 | 2020-02-18 | 2024-03-19 |
| Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Belatacept, Tacrolimus, ATG - Lung Transplant Rejection, Antibody-mediated Rejection | Phase 2 | Completed | Washington University School of Medicine | 27 | 2019-12-17 | 2022-11-25 |
Showing 20 of 39. Sign in to see all of them.
Kidney Failure, Chronic (2) · Rejection, Psychology (2) · Bronchiolitis Obliterans (1) · Bronchiolitis Obliterans Syndrome (1) · Chronic Disease (1) · Complement Component 3 Deficiency, Autosomal Recessive (1) · Hematologic Diseases (1) · Kidney Diseases (1) · Neuromyelitis Optica (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Ventricular Dysfunction, Left (1)
Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Behavior (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Immune System Diseases (2) · Male Urogenital Diseases (2) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Social Behavior (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Autoimmune Diseases (1)
clazakizumab (4) · Methylprednisolone (3) · daratumumab (3) · felzartamab (3) · Abatacept (2) · Bortezomib (2) · Immunoglobulins, Intravenous (2) · Saline Solution (2) · eculizumab (2) · Azathioprine (1) · Complement C1 Inhibitor Protein (1) · Coronary Angiography (1) · Echocardiography (1) · Immunoglobulins (1) · Immunosuppression Therapy (1)
Medical University of Vienna (4) · Biogen (2) · CSL Behring (2) · Stanley Jordan, MD (2) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Brigham and Women's Hospital (1) · Cedars-Sinai Medical Center (1) · Charite University, Berlin, Germany (1) · Charles M Knudson (1) · Children's Hospital of Philadelphia (1) · Duke University (1) · Farsad Eskandary (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · First Affiliated Hospital of Zhejiang University (1)
United States (14) · Austria (8) · Germany (8) · France (7) · Spain (7) · Canada (6) · China (5) · Belgium (4) · Czechia (3) · Netherlands (3) · South Korea (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Italy (2)
Jianyong Wu, MD (2) · Stanley Jordan, MD (2) · Alberto Benazzo, MD PhD (1) · Anil K Chandraker, MD (1) · Bernd Jilma, MD (1) · Brendan Keating, DPhil (1) · Halil Yazici, MD (1) · Hendrikus Otten, PhD (1) · Jaeseok Yang, M.D., Ph.D (1) · Jan T Kielstein, Prof. (1) · Jignesh Patel, M.D., Ph.D. (1) · Juan F Delgado, MD PhD (1)
PMID 40444214, PMID 38804514, PMID 10580071, PMID 24708575, PMID 24900946, PMID 26147651, PMID 26281144, PMID 26308596, PMID 30635033, PMID 31167061, PMID 31227636, PMID 31373158, PMID 31419065, PMID 31530561, PMID 32243663, PMID 32251496, PMID 32670261, PMID 33239394, PMID 33251691, PMID 33332922, PMID 33443079, PMID 33871888, PMID 33956337, PMID 34153143, PMID 34228654, PMID 34498551, PMID 34863025, PMID 35395951, PMID 35497778, PMID 35573002, PMID 35757730, PMID 35892015, PMID 35935024, PMID 35969004, PMID 36127770, PMID 36201223, PMID 36287047, PMID 36382130, PMID 36550562, PMID 37182818, PMID 37322595, PMID 37899481, PMID 38519988, PMID 39102302, PMID 39134120, PMID 39147695, PMID 39479216, PMID 39673311, PMID 39780312, PMID 40440205
2017 (2), 2018 (2), 2019 (1), 2023 (1), R01HD091185 (1)